SCM
FRTX

Stonepine Capital Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Stonepine Capital Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,261
Closed -$147K – 19
2020
Q2 		$147K Buy
+3,261
New +$174K 0.28% 13
2018
Q1 		– Sell
-2,147
Closed -$1.24M – 37
2017
Q4 		$1.24M Buy
+2,147
New +$1.41M 0.74% 23

Other funds holding FRTX

PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSWM
Smith Salley Wealth Management Greensboro, North Carolina $1.99B AUM 25.19% 1-Year Est. Return

Stonepine Capital Management's FRTX Position: Q3 2020 in Review

Stonepine Capital Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2020, closing a stake of 3,261 shares — an estimated $147K sold.

Stonepine Capital Management first reported a position in FRTX in Q4 2017 and held it in 2 quarters. The position peaked at $1.24M in Q4 2017. 17 funds tracked by Wall St. Rank hold FRTX as of Q3 2020.

  • Stonepine Capital Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Stonepine Capital Management sold 3,261 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $147K.
  • Stonepine Capital Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Stonepine Capital Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.24M in Q4 2017.
  • 17 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Stonepine Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.